全球特发性肺纤维化治疗市场研究报告 - 2024 年至 2032 年产业分析、规模、份额、成长、趋势与预测

全球特发性肺纤维化治疗市场的需求预计将从2023年的45.4亿美元达到2032年近138.4亿美元的市场规模，2024-2032年研究期间的复合年增长率为13.18%。

特发性肺纤维化 (IPF) 是一种慢性进行性肺部疾病，其特征是肺部疤痕组织累积（纤维化），导致呼吸障碍和氧气吸收减少。 IPF 的确切病因尚不清楚，因此为特发性。这种情况会导致持续咳嗽、气短和肺功能进行性下降。特发性肺纤维化治疗方案旨在减缓疾病的进展、控制症状并改善生活品质。这些可能包括针对纤维化过程的抗纤维化药物，例如吡非尼酮和尼达尼布，以及氧气治疗和肺部復健等支持疗法。治疗的目标是稳定肺功能、缓解症状并提供支持性护理以提高患者的整体健康状况。

市场动态

由于 IPF 盛行率的不断增加、其进行性以及相关的未满足的医疗需求，特发性肺纤维化治疗市场正在经历成长。随着全球人口老化和对 IPF 认识的提高，对能够解决这种具有挑战性的疾病的复杂性的治疗方法的需求不断增长。研究和药物开发的进步是市场成长的重要驱动力。吡非尼酮和尼达尼布等抗纤维化疗法的最新突破已证明可减缓疾病进展和改善患者预后。对新型治疗药物和联合疗法的持续研究为 IPF 管理的进一步进步提供了潜力。基于遗传和分子谱的标靶治疗和个人化医疗方法的发展也为特发性肺纤维化治疗市场的扩张提供了机会。对临床试验和研究计划的投资增加有助于特发性肺纤维化治疗市场的成长。製药公司、研究机构和医疗保健提供者之间的合作旨在增进对该疾病的了解并开发创新疗法。此外，扩大医疗基础设施和改善获得专业护理的机会可以提高 IPF 疗法的可用性和采用率。对以患者为中心的方法和支持性护理策略的日益关注进一步支持了市场成长。整合药物和非药物干预措施的患者宣传、教育和综合护理模式有助于改善患者的生活品质并支持整体疾病管理。然而，高昂的治疗成本和有限的患者访问可能会限制市场成长。

研究报告涵盖波特五力模型、市场吸引力分析和价值链分析。这些工具有助于清晰地了解行业结构并评估全球范围内的竞争吸引力。此外，这些工具也对全球特发性肺纤维化治疗市场的各个细分市场进行了包容性评估。特发性肺纤维化治疗产业的成长和趋势为本研究提供了整体方法。

市场区隔

特发性肺纤维化治疗市场报告的这一部分提供了有关国家和区域级别细分市场的详细资料，从而帮助策略师确定相应产品或服务的目标人口统计数据以及即将到来的机会。

按药物类别

• Mapk 抑制剂 (Esbriet)
• 酪胺酸抑制剂（Ofev）
• 自分泌运动因子抑制剂 (GLPG 1690)

区域分析

本节涵盖区域前景，重点介绍北美、欧洲、亚太地区、拉丁美洲以及中东和非洲特发性肺纤维化治疗市场当前和未来的需求。此外，该报告重点关注所有主要地区各个应用领域的需求、估计和预测。

该研究报告还涵盖了市场主要参与者的全面概况以及对全球竞争格局的深入了解。特发性肺纤维化治疗市场的主要参与者包括霍夫曼·拉罗氏有限公司、勃林格殷格翰国际有限公司、Galapagos、FibroGen Inc.、Prometic Life Sciences Inc.、百时美施贵宝公司、MediciNova Inc .、默克公司。 、新产品发布，以及其他进度。

如果您有任何客製化要求，请写信给我们。我们的研究团队可以根据您的需求提供客製化报告。

目录

第一章：前言

• 报告说明
  • 客观的
  • 目标受众
  • 独特的销售主张 (USP) 和产品
• 研究范围
• 研究方法
  • 市场研究过程
  • 市场研究方法论

第 2 章：执行摘要

• 市集亮点
• 全球市场概况

第 3 章：特发性肺纤维化治疗 - 产业分析

• 简介 - 市场动态
• 市场驱动因素
• 市场限制
• 机会
• 产业动态
• 波特五力分析
• 市场吸引力分析
  • 按药品类别分類的市场吸引力分析
  • 市场吸引力分析：按地区

第 4 章：价值链分析

• 价值链分析
• 原料分析
  • 原料清单
  • 原料厂商清单
  • 主要原物料价格走势
• 潜在买家名单
• 行销管道
  • 直效行销
  • 间接行销
  • 行销通路发展趋势

第 5 章：全球特发性肺纤维化治疗市场分析：依药物类别

• 按药物类别概述
• 按药物类别进行历史和预测数据分析
• Mapk 抑制剂 (Esbriet)
• 酪胺酸抑制剂（Ofev）
• 自分泌运动因子抑制剂 (GLPG 1690)

第 6 章：全球特发性肺纤维化治疗市场分析：按地理位置

• 区域展望
• 介绍
• 北美销售分析
  • 概览、历史与预测资料销售分析
  • 北美按细分市场销售分析
  • 北美按国家销售分析
  • 美国销售分析
  • 加拿大销售分析
  • 墨西哥销售分析
• 欧洲销售分析
  • 概览、历史与预测资料销售分析
  • 欧洲按细分市场销售分析
  • 欧洲按国家销售分析
  • 英国销售分析
  • 法国销售分析
  • 德国销售分析
  • 义大利销售分析
  • 俄罗斯销售分析
  • 欧洲其他地区销售分析
• 亚太地区销售分析
  • 概览、历史与预测资料销售分析
  • 亚太地区按细分市场销售分析
  • 亚太地区按国家销售分析
  • 中国销售分析
  • 印度销售分析
  • 日本销售分析
  • 韩国销售分析
  • 澳洲销售分析
  • 东南亚销售分析
  • 亚太地区其他地区销售分析
• 拉丁美洲销售分析
  • 概览、历史与预测资料销售分析
  • 拉丁美洲按细分市场销售分析
  • 拉丁美洲按国家销售分析
  • 巴西销售分析
  • 阿根廷销售分析
  • 秘鲁销售分析
  • 智利销售分析
  • 拉丁美洲其他地区销售分析
• 中东和非洲销售分析
  • 概览、历史与预测资料销售分析
  • 中东和非洲按细分市场销售分析
  • 中东和非洲按国家销售分析
  • 沙乌地阿拉伯销售分析
  • 阿联酋销售分析
  • 以色列销售分析
  • 南非销售分析
  • 中东其他地区和非洲销售分析

第 7 章：特发性肺纤维化治疗公司的竞争格局

• 特发性肺纤维化治疗市场竞争
• 伙伴关係/协作/协议
• 併购
• 新产品发布
• 其他发展

第 8 章：公司简介

• 顶级公司市占率分析
• 市场集中度
• F. Hoffman La-Roche Ltd
• 公司概况
• 公司收入
• 产品
• 最新动态
• Boehringer Ingelheim International GmbH
• 公司概况
• 公司收入
• 产品
• 最新动态
• Galapagos
• 公司概况
• 公司收入
• 产品
• 最新动态
• FibroGen Inc.
• 公司概况
• 公司收入
• 产品
• 最新动态
• Prometic Life Sciences Inc.
• 公司概况
• 公司收入
• 产品
• 最新动态
• Bristol-Myers Squibb Company
• 公司概况
• 公司收入
• 产品
• 最新动态
• MediciNova Inc.
• 公司概况
• 公司收入
• 产品
• 最新动态
• Merck & Co. Inc.
• 公司概况
• 公司收入
• 产品
• 最新动态
• Novartis AG
• 公司概况
• 公司收入
• 产品
• 最新动态
• Merck & Co
• 公司概况
• 公司收入
• 产品
• 最新动态

註 - 在公司概况中，财务详细资讯和最新发展视情况而定，或对私人公司而言可能不包括在内

The global demand for Idiopathic Pulmonary Fibrosis Treatment Market is presumed to reach the market size of nearly USD 13.84 Billion by 2032 from USD 4.54 Billion in 2023 with a CAGR of 13.18% under the study period 2024-2032.

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive lung disease characterized by accumulated scar tissue (fibrosis) in the lungs, leading to respiratory impairment and decreased oxygen absorption. The exact cause of IPF is unknown, making it idiopathic. The condition results in persistent cough, shortness of breath, and progressive lung function decline. Idiopathic pulmonary fibrosis treatment options are designed to slow the progression of the disease, manage symptoms, and enhance quality of life. These may include antifibrotic medications, such as pirfenidone and nintedanib, which target the fibrosis process, and supportive therapies like oxygen therapy and pulmonary rehabilitation. The goal of treatment is to stabilize lung function, alleviate symptoms, and provide supportive care to enhance patients' overall well-being.

MARKET DYNAMICS

The idiopathic pulmonary fibrosis treatment market is experiencing growth driven by the increasing prevalence of IPF, its progressive nature, and the associated high unmet medical need. As the global population ages & awareness of IPF rises, there is a growing need for therapies that can address the complexities of this challenging condition. Advancements in research and drug development are significant drivers of market growth. Recent breakthroughs in antifibrotic therapies, such as pirfenidone and nintedanib, have demonstrated efficacy in slowing disease progression and improving patient outcomes. Ongoing research into novel therapeutic agents and combination therapies offers potential for further advancements in IPF management. The development of targeted treatments & personalized medicine approaches based on genetic and molecular profiles also presents opportunities for idiopathic pulmonary fibrosis treatment market expansion. Increased investment in clinical trials and research initiatives contributes to the growth of the idiopathic pulmonary fibrosis treatment market. Collaborative efforts between pharmaceutical companies, research institutions, and healthcare providers aim to advance understanding of the disease and develop innovative treatments. Additionally, expanding healthcare infrastructure and improved access to specialized care enhance the availability and adoption of IPF therapies. The rising focus on patient-centric approaches and supportive care strategies further supports market growth. Patient advocacy, education, and comprehensive care models integrating pharmacologic and non-pharmacologic interventions help improve patient quality of life and support overall disease management. However, high treatment costs and limited patient access may restrain market growth.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Idiopathic Pulmonary Fibrosis Treatment. The growth and trends of Idiopathic Pulmonary Fibrosis Treatment industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Idiopathic Pulmonary Fibrosis Treatment market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Drug Class

• Mapk Inhibitors (Esbriet)
• Tyrosine Inhibitors (Ofev)
• Autotaxin Inhibitors (GLPG 1690)

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Idiopathic Pulmonary Fibrosis Treatment market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Idiopathic Pulmonary Fibrosis Treatment market include F. Hoffman La-Roche Ltd, Boehringer Ingelheim International GmbH, Galapagos, FibroGen Inc., Prometic Life Sciences Inc., Bristol-Myers Squibb Company, MediciNova Inc., Merck & Co. Inc., Novartis AG, Merck & Co. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1. PREFACE

• 1.1. Report Description
  • 1.1.1 Objective
  • 1.1.2 Target Audience
  • 1.1.3 Unique Selling Proposition (USP) & offerings
• 1.2. Research Scope
• 1.3. Research Methodology
  • 1.3.1 Market Research Process
  • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

• 2.1. Highlights of Market
• 2.2. Global Market Snapshot

3. IDIOPATHIC PULMONARY FIBROSIS TREATMENT - INDUSTRY ANALYSIS

• 3.1. Introduction - Market Dynamics
• 3.2. Market Drivers
• 3.3. Market Restraints
• 3.4. Opportunities
• 3.5. Industry Trends
• 3.6. Porter's Five Force Analysis
• 3.7. Market Attractiveness Analysis
  • 3.7.1 Market Attractiveness Analysis By Drug Class
  • 3.7.2 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

• 4.1. Value Chain Analysis
• 4.2. Raw Material Analysis
  • 4.2.1 List of Raw Materials
  • 4.2.2 Raw Material Manufactures List
  • 4.2.3 Price Trend of Key Raw Materials
• 4.3. List of Potential Buyers
• 4.4. Marketing Channel
  • 4.4.1 Direct Marketing
  • 4.4.2 Indirect Marketing
  • 4.4.3 Marketing Channel Development Trend

5. GLOBAL IDIOPATHIC PULMONARY FIBROSIS TREATMENT MARKET ANALYSIS BY DRUG CLASS

• 5.1. Overview By Drug Class
• 5.2. Historical and Forecast Data Analysis By Drug Class
• 5.3. Mapk Inhibitors (Esbriet) Historic and Forecast Sales By Regions
• 5.4. Tyrosine Inhibitors (Ofev) Historic and Forecast Sales By Regions
• 5.5. Autotaxin Inhibitors (GLPG 1690) Historic and Forecast Sales By Regions

6. GLOBAL IDIOPATHIC PULMONARY FIBROSIS TREATMENT MARKET ANALYSIS BY GEOGRAPHY

• 6.1. Regional Outlook
• 6.2. Introduction
• 6.3. North America Sales Analysis
  • 6.3.1 Overview, Historic and Forecast Data Sales Analysis
  • 6.3.2 North America By Segment Sales Analysis
  • 6.3.3 North America By Country Sales Analysis
  • 6.3.4 United States Sales Analysis
  • 6.3.5 Canada Sales Analysis
  • 6.3.6 Mexico Sales Analysis
• 6.4. Europe Sales Analysis
  • 6.4.1 Overview, Historic and Forecast Data Sales Analysis
  • 6.4.2 Europe By Segment Sales Analysis
  • 6.4.3 Europe By Country Sales Analysis
  • 6.4.4 United Kingdom Sales Analysis
  • 6.4.5 France Sales Analysis
  • 6.4.6 Germany Sales Analysis
  • 6.4.7 Italy Sales Analysis
  • 6.4.8 Russia Sales Analysis
  • 6.4.9 Rest Of Europe Sales Analysis
• 6.5. Asia Pacific Sales Analysis
  • 6.5.1 Overview, Historic and Forecast Data Sales Analysis
  • 6.5.2 Asia Pacific By Segment Sales Analysis
  • 6.5.3 Asia Pacific By Country Sales Analysis
  • 6.5.4 China Sales Analysis
  • 6.5.5 India Sales Analysis
  • 6.5.6 Japan Sales Analysis
  • 6.5.7 South Korea Sales Analysis
  • 6.5.8 Australia Sales Analysis
  • 6.5.9 South East Asia Sales Analysis
  • 6.5.10 Rest Of Asia Pacific Sales Analysis
• 6.6. Latin America Sales Analysis
  • 6.6.1 Overview, Historic and Forecast Data Sales Analysis
  • 6.6.2 Latin America By Segment Sales Analysis
  • 6.6.3 Latin America By Country Sales Analysis
  • 6.6.4 Brazil Sales Analysis
  • 6.6.5 Argentina Sales Analysis
  • 6.6.6 Peru Sales Analysis
  • 6.6.7 Chile Sales Analysis
  • 6.6.8 Rest of Latin America Sales Analysis
• 6.7. Middle East & Africa Sales Analysis
  • 6.7.1 Overview, Historic and Forecast Data Sales Analysis
  • 6.7.2 Middle East & Africa By Segment Sales Analysis
  • 6.7.3 Middle East & Africa By Country Sales Analysis
  • 6.7.4 Saudi Arabia Sales Analysis
  • 6.7.5 UAE Sales Analysis
  • 6.7.6 Israel Sales Analysis
  • 6.7.7 South Africa Sales Analysis
  • 6.7.8 Rest Of Middle East And Africa Sales Analysis

7. COMPETITIVE LANDSCAPE OF THE IDIOPATHIC PULMONARY FIBROSIS TREATMENT COMPANIES

• 7.1. Idiopathic Pulmonary Fibrosis Treatment Market Competition
• 7.2. Partnership/Collaboration/Agreement
• 7.3. Merger And Acquisitions
• 7.4. New Product Launch
• 7.5. Other Developments

8. COMPANY PROFILES OF IDIOPATHIC PULMONARY FIBROSIS TREATMENT INDUSTRY

• 8.1. Top Companies Market Share Analysis
• 8.2. Market Concentration Rate
• 8.3. F. Hoffman La-Roche Ltd
  • 8.3.1 Company Overview
  • 8.3.2 Company Revenue
  • 8.3.3 Products
  • 8.3.4 Recent Developments
• 8.4. Boehringer Ingelheim International GmbH
  • 8.4.1 Company Overview
  • 8.4.2 Company Revenue
  • 8.4.3 Products
  • 8.4.4 Recent Developments
• 8.5. Galapagos
  • 8.5.1 Company Overview
  • 8.5.2 Company Revenue
  • 8.5.3 Products
  • 8.5.4 Recent Developments
• 8.6. FibroGen Inc.
  • 8.6.1 Company Overview
  • 8.6.2 Company Revenue
  • 8.6.3 Products
  • 8.6.4 Recent Developments
• 8.7. Prometic Life Sciences Inc.
  • 8.7.1 Company Overview
  • 8.7.2 Company Revenue
  • 8.7.3 Products
  • 8.7.4 Recent Developments
• 8.8. Bristol-Myers Squibb Company
  • 8.8.1 Company Overview
  • 8.8.2 Company Revenue
  • 8.8.3 Products
  • 8.8.4 Recent Developments
• 8.9. MediciNova Inc.
  • 8.9.1 Company Overview
  • 8.9.2 Company Revenue
  • 8.9.3 Products
  • 8.9.4 Recent Developments
• 8.10. Merck & Co. Inc.
  • 8.10.1 Company Overview
  • 8.10.2 Company Revenue
  • 8.10.3 Products
  • 8.10.4 Recent Developments
• 8.11. Novartis AG
  • 8.11.1 Company Overview
  • 8.11.2 Company Revenue
  • 8.11.3 Products
  • 8.11.4 Recent Developments
• 8.12. Merck & Co
  • 8.12.1 Company Overview
  • 8.12.2 Company Revenue
  • 8.12.3 Products
  • 8.12.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies

LIST OF TABLES

• Market Snapshot
• Drivers: Impact Analysis
• Restraints: Impact Analysis
• List of Raw Material
• List of Raw Material Manufactures
• Analysis By Drug Class (USD MN)
• Mapk Inhibitors (Esbriet) Market Sales By Geography (USD MN)
• Tyrosine Inhibitors (Ofev) Market Sales By Geography (USD MN)
• Autotaxin Inhibitors (GLPG 1690) Market Sales By Geography (USD MN)
• Global Idiopathic Pulmonary Fibrosis Treatment Market Sales By Geography (USD MN)
• North America Market Analysis (USD MN)
• United States Market Analysis (USD MN)
• Canada Market Analysis (USD MN)
• Mexico Market Analysis (USD MN)
• Europe Market Analysis (USD MN)
• Europe Market Estimate By Country (USD MN)
• United Kingdom Market Analysis (USD MN)
• France Market Analysis (USD MN)
• Germany Market Analysis (USD MN)
• Italy Market Analysis (USD MN)
• Russia Market Analysis (USD MN)
• Spain Market Analysis (USD MN)
• Rest of Europe Market Analysis (USD MN)
• Asia Pacific Market Analysis (USD MN)
• China Market Analysis (USD MN)
• Japan Market Analysis (USD MN)
• India Market Analysis (USD MN)
• South Korea Market Analysis (USD MN)
• Australia Market Analysis (USD MN)
• South East Asia Market Analysis (USD MN)
• Rest of Asia Pacific Market Analysis (USD MN)
• Latin America Market Analysis (USD MN)
• Brazil Market Analysis (USD MN)
• Argentina Market Analysis (USD MN)
• Peru Market Analysis (USD MN)
• Chile Market Analysis (USD MN)
• Rest of Latin America Market Analysis (USD MN)
• Middle East & Africa Market Analysis (USD MN)
• Saudi Arabia Market Analysis (USD MN)
• UAE Market Analysis (USD MN)
• Israel Market Analysis (USD MN)
• South Africa Market Analysis (USD MN)
• Rest of Middle East and Africa Market Analysis (USD MN)
• Partnership/Collaboration/Agreement
• Mergers And Acquisition

LIST OF FIGURES

• Research Scope of Idiopathic Pulmonary Fibrosis Treatment Report
• Market Research Process
• Market Research Methodology
• Global Idiopathic Pulmonary Fibrosis Treatment Market Size, By Region (USD MN)
• Porters Five Forces Analysis
• Market Attractiveness Analysis By Drug Class
• Market Attractiveness Analysis By Region
• Value Chain Analysis
• Global Market Analysis By Drug Class (USD MN)
• Mapk Inhibitors (Esbriet) Market Sales By Geography (USD MN)
• Tyrosine Inhibitors (Ofev) Market Sales By Geography (USD MN)
• Autotaxin Inhibitors (GLPG 1690) Market Sales By Geography (USD MN)
• Global Market Sales (USD MN)
• North America Market Sales (USD MN)
• Europe Market Sales (USD MN)
• Asia Pacific Market Sales (USD MN)
• Latin America Market Sales (USD MN)
• Middle East & Africa Market Sales (USD MN)
• Recent Development in Industry
• Top Company Market Share Analysis

Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.